Abstract 626P
Background
Circulating tumor DNA (ctDNA) analysis with comprehensive panels is now integral to cancer genomic profiling, advancing precision medicine in clinical practice. Yet, the practicality of treatment post ctDNA testing remains uncertain. This study aims to estimate treatment application post ctDNA analysis and its clinical utility.
Methods
Over a 7-month period, from January to July 2023, we retrospectively evaluated 102 patients with solid tumors who underwent ctDNA using the next generation sequencing method at a university-affiliated tertiary care hospital in Korea. To determine the percentage of genome-driven targeted therapy applied subsequent to ctDNA test result, we employed previously reported FDA-approved companion diagnostic biomarkers and their corresponding drug lists. Cases in which FDA-approved targeted therapy was prescribed or cases in which drugs were changed due to drug resistance after ctDNA testing were assessed.
Results
Out of 102 cases evaluated, 81 cases (79.4%) displayed ctDNA sequencing results featuring actionable variants classified as Tier 1 or Tier II. Among the 73 FDA-approved drugs, 12 were administered at our hospital between January 1, 2023, and July 31, 2023. According to ctDNA results, 21 individuals (20.6% of the total cases) were either prescribed FDA-approved drugs or underwent drug changes. Among them, 15 patients (14.7%) were prescribed FDA-approved drugs, while 6 patients (5.9%) experienced alterations in their medication regimens. Of the 21 patients undergoing targeted therapy based on ctDNA test results, colorectal cancer (12/21, 57.1%) was the most prevalent, followed by NSCLC (4/21, 19.0%). Consistent with these cancer types, the most frequently administered drugs were pembrolizumab (8/21, 38.1%) and cetuximab (6/21, 28.6%).
Conclusions
While this study presents findings from an investigation at a tertiary-hospital in Korea, it underscores the significant prevalence of genome-targeted therapy adoption following ctDNA testing for solid tumors. A larger-scale study should be pursued to further validate these observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract